2024-03-31-accounts

breast cancer uk. Prevention saves lives IMPACT REPORT ANDACCOUNTS 2023/24 Breast Cancer UK Ltd Charity No. 11388661 Company No. 7348408

breast cancer uk. ABOUT BREAST CANCER UK Our charitable objectives Our guiding principles Impact Report / A word from the Chair and CEO OUR SCIENCE PROGRAMME 8-15 10-13 14-15 Breast Cancer UK'S Grant Funding Programme Breast Cancer Prevention Conference OUR EDUCATION PROGRAMME 16-19 Prevention hub and education content Plans for our educational programme 17-18 19 OUR ADVOCACY PROGRAMME 20-23 Advocacy and campaigning Collaboration Next Steps 21 22 22-23 OUR GENEROUS SUPPORTERS Regular Giving (The B Well Club) Community and Events Fundraising In Memory Gifts and Legacies Corporate Partnerships 24-28 25 26-27 28 FINANCIAL REVIEW 29-32 30 30-31 31-32 32 Principal funding sources Charitable Expenditure Reserves policy Results and closing position STRUCTURE GOVERNANCE AND MANAGEMENT 33-37 Structure Governance Staff Risk Management Statement of public benefit Statement of Trustees Responsibilities for the Year Ended 31 March 2024 Auditor's report FINANCIAL STATEMENTS 34 34 35 35 36 37 38-40 41-53

ABOUT BREAST CANCER UK Around 55,500 women and 370 men in the UK are diagnosed with breast cancer every year and it is predicted that l in 7 women will get breast cancer at some point in their lives. Yet, at least 30/0 of breast cancers are preventable. That means that around 17,000 cases of breast cancer could be prevented each year, saving countless lives, reducing suffering and reducing the cost to the N HS. We believe there are many opportunities to reduce breast cancer rates in the UK potentially saving millions of lives as a result. We give practical advice on how people can reduce their risk of getting breast cancer by making simple changes in their lives. A unique aspect of our work focuses on the role played by hormone disrupting chemicals in increasing the risk of breast cancer and we work with other organisations to make our voice heard on this issue. We also fund research that we believe could be a game-changer in the field of breast cancer prevention. Our mission is to prevent suffering caused by preventable breast cancers through funding research, supporting individual behavioural change and campaigning for effective public health and environmental protections. We believe our work can have a significant impact on helping women and men reduce their risk of developing breast cancer. BREAST CANCER RATES DOUBLED IN 50 YEARS +24/0 SINCE 1996 AWOMAN'S LIFETIME RISK OF BREAST CANCER IS 1 IN 7 56,000 women diagnosed with breast cancer every year (for UK women born after 1960} ++++++i

96/. of breast cancers appear in women over 40 56,000 Women diagnosed with breast cancer each year in the UK Breast cancer is the 400 othmon Men diagnosed with breast cancer each year in the UK cancer in the UK 30% of breast cancer cases can be prevented Women will develop breast cancer at some point in their lives. 17,000 Cases of breast cancer that could be prevented each year

WE EDUCATE AND RAISE AWARENESS OF THE PREVENTABLE RISK FACTORS FOR BREAST CANCERAND PROVIDE PRACTICAL INFORMATION TO HELP PEOPLE REDUCE THEIR RISK OUR CHARITABLE OBJECTIVES WE CAMPAIGN FOR POLICIES THAT SUPPORT THE PREVENTION OF BREAST CANCER WE SUPPORT SCIENTIFIC RESEARCH THAT HELPS TO UNDERSTAND AND ADDRESS THE PREVENTABLE RISK FACTORS FOR BREAST CANCER OUR GUIDING PRINCIPLES: Breast Cancer UK believes prevention is possible: more can be done to prevent breast cancers by tackling lifestyle and environmental risk factors. We are evidence based: scientific evidence is at the heart of our work with sources clearly identified. We champion high environmental and ethical standards: partnering with companies and suppliers whose own ethical and environmental policies match these standards. We believe in the right to know.. we want to empower people by giving them the information they need about the preventable risk factors for breast cancer, so they can make informed choices. We believe in collaboration: we will actively identify, seek and establish collaborations with other stakeholders le.g. charities, think tanks, companies, government and scientific institutions) to ensure we are effective in delivering our goals.

WELCOME TO OUR 2023/24 IMPACT REPORT A WORD FROM OUR CHAIRAND CEO We are delighted to share our Impact Report and Accounts for the financial year 2023/24. Our mission to make breast cancer prevention a reality is a great challenge that we believe can be achieved through directly appealing to and nurturing our supporters, collaborating with those who share our passion and determination and investing in high-quality research 2nd education. This year we took strides towards reaching this ambition by strengthening our visibility through an expansion of our science-backed content and personalised advice, striving to match the needs of our supporters. We saw demand swell for our prevention education as we empowered greater numbers of people to take prevention into their own hands with our prevention quiz. We reached a significant milestone this year in hosting our first Breast Cancer Prevention Conference, proudly partnering with Middlesex University. The conference ignited new conversations and debates between scientists and experts across the health and environmental prevention research sectors, exploring the evidence, the gaps in our understanding and the priorities to act upon. We strengthened our scientific grant programme with a steady investment in new research grants and through new funding opportunities to cultivate greater interest and diversify this important field of research. This year's achievements enabled us to edge closer to our strategic targets, to grow our scientific programme and investment, widen the impact of our education through significantly expanding access to our personalised prevention planners, empowering more people to make breast cancer prevention a part of their lives. Our charity is entirely dependent on the generous donations of people, businesses, groups, clubs, schools, trust & foundations and associations who believe in and Want to support our work. Our achievements would not have happened without their support. This year our growing number of supporters helped our charity sustain financial growth for the third year running enabling greater investments in our science and education. For this, we want to express our deepest gratitude and appreciation. We wholeheartedly thank all of our valued supporters. Our engaged Board of Trustees oversaw the governance of our team and represented our charity with passion and commitment bringing a rich mix of skills and experiences. We were delighted to welcome Beezy Marsh who is an author 2nd journ21ist, N2Zi2 Tingay who is a Senior Payments Project Manager, Lotte Spencer who is a Marketing Director and Silvy Mardiguian who is Head of Economics and Outcomes Research.

We were sad to say goodbye to Dr Britta Stordal, our Deputy Chair and Chair of our Science and Public Affairs Committee. Britta's investment in the charity and her skills, insights and passion have brought significant value to our cause. We thank her for her commitment. We also said goodbye to Nichole Taske, who also served on our Science and Public Affairs Committee bringing invaluable public health policy knowledge to the charity. We thank Nichole for her commitment. Finally, we farewelled Charlie Winstanley who also served on our Science and Public Affairs Committee, bringing a breadth of policy and public health knowledge. We thank him for his commitment. Our passionate and talented team continued to expand to meet the swell in demand for our work. With this growth comes a greater mix of skills, backgrounds and experience enriching the work that we do. The team's tireless commitment to achieving impact is hugely appreciated. Their feedback has told us that they love working together to achieve one goal and that they feel their contribution is making a difference. We thank all of our colleagues for their commitment and dedication. This year has shown that we can achieve our ambition and strive for more. As we enter the last year of our strategic plan we remain steadfast in our commitment to put breast cancer prevention at the core of the public health and environmental responses to this devasting disease. We look forward to continuing to stride forward with our supporters and partners to make preventing this disease a priority. Ruth Freeborough Chair, Breast Cancer UK Thalie Martini CEO, Breast Cancer UK

OUR SCIENCE PROGRAMME

Our objectives were to; Support high-quality, independent scientific research projects at universities or research institutes within the UK. Bring relevant, high-quality data and new research findings into the public arena Grow our scientific expertise and reputation in the field of breast cancer prevention A key mission of ours is to understand the preventable causes of breast cancer so that we can translate this into practical measures that help reduce the impact of breast cancer on people's lives. Our science programme is dedicated to exploring the link between breast cancer and potentially harmful chemicals found in everyday products and in our environment. We have made this our focus as we believe that there is an urgent need to build greater evidence around the harms these chemicals may be causing to our health and our breast cancer risk. While there is convincing evidence to show that lifestyle factors such as alcohol consumption and obesity can influence breast cancer risk, there is less wide- ranging evidence available on the effects of environmental chemicals and possible links with breast cancer. Our grants programme aims to help fill the gap in our knowledge and understanding of this complex area of breast cancer risk.

BREAST CANCER UK'S GRANT FUNDING PROGRAMME RESEARCH PROJECTS Completed projects Brunel University London Examining how Endocrine Disrupting Chemicals {EDCs) mixtures and a high-fat diet affect breast cancer Dr Elisabete Silva, Brunel University The project examined the impact of mixtures of Endocrine Disrupting Chemicals {EDC5) and saturated fats (that may result from a high fat diet) on early stages of breast cancer. Findings from this project showed that 3D spheroids of normal breast cells exposed to a mixture of Endocrine Disrupting Chemicals (EDCS) 2nd saturated fats resulted in a more deformed structure compared to non-exposed cells. This project also validated an exciting new three-dimensional breast cancer model system known 25 "Breast-on-chip" This model contained three prominent cell types found in the breast and more closely resembled how breast cells behave in the body. The model will make future experiments involving mixtures of Endocrine Disrupting Chemica15 IEDCs)/saturated fats more human-relevant. UNIVERSITY Current Projects .fHULL Investigating effects of per- and poly-fluoroalkyl (PFAS, or per- and polyfluoroalkyl substances) substances on breast cancer development February 2024 - Present This PhD studentship project was awarded to Dr Mark Wade and PhD student Ms Lucie Bilton of the University of Hull. This project aims to investigate whether PFAS, or per- and polyfluoroalkyl substances ("forever chemicals") play a role in breast cancer development and determine whether microplastlCS that can leach PFAS, or per- and polyfluoroalkyl substances are found in breast tissue. Normal breast cells will be exposed to PFAS, or per- and polyfluoroalkyl substances at levels found in the blood and then be assessed for characteristics often found in cancerous cells. The effect of long and short-term exposure will be an21ysed to see what changes occur immediately and which develop over time. Breast tissue from patients will also be analysed for microplastics. 10

College LONDON Measurement of Endocrine Disrupting Chemicals (EDCS) in breast cancer November 2023- Present This 18-month project was awarded to Dr Michael Antoniou with Research Assistant, Charlotte O'Hern, at King's College London. This project aims to assess the potential risks arising from Endocrine Disrupting Chemicals (EDCS) found in everyday products that can potentially lead to or promote breast cancer. Frozen breast cancer samples will be screened for oestrogen-like chemical pollutants. Cancer and non-cancerous fatty tissue from the same breast will be analysed. The results will be used to assess if there is a connection between the amount and type of oestrogen-like chemical pollutants detected and breast cancer growth and spread. IWI UNIVERSITY OF ABERDEEN Evaluating the effects of BPA on breast cancer development February 2023 - Present This PhD studentship project was awarded to Prof Val Speirs and her PhD student Ms Katharin2 Kusserow at the University of Aberdeen. This project is investigating the effect of bisphenol A {BPA) on the non-cancerous breast and how it may contribute to breast cancer development. The project will involve a systematic review of existing literature to assess the current understanding of how BPA affects breast tissue and computer-based 2ppr02ches to identify genes related to BPA exposure. Laboratory experiments will then assess any potential involvement of those selected genes in breast cancer development. BPA levels will also be measured in blood samples donated by breast cancer patients. College LONDON Biomonitoring 2nd molecular toxicity profiling of bisphenol mixtures February 2022 - Present This PhD studentship was awarded to Dr Michael Antoniou and his PhD student Connor Powell at King's College London. This research project aims to complete a biomonitoring study where urine samples are collected from the general public and analysed for bisphenol compounds to help determine the levels of bisphenol exposure in the UK population. 11

Publications Di Pasquale A. Endocrine Disrupting Chemicals: the role they play in breast cancer. Open Access Government. 2024. https://www.openaccessgovernment.org/endocrine-disrupting-chemicals-the- role-they-play-in-breast-cancer/1749631 Powell C, Mesnage R, Antoniou MN, Vandenberg LN. Low dose effects of environmental chemicals: Bisphenol A as a case study. Encyclopedia of Toxicology, Fourth Edition: Volume 1-9 2024.5.955-67 https://doi.org/lO.1016/B978-0-12- 824315-2.00762-4 A NEW STRUCTURE FOR OUR GRANT APPLICATION ROUND 2023/24 Our most recent funding round called for applications that focus on the relationship between Endocrine Disrupting Chemicals {EDCs) and breast cancer risk" this was launched in November 2023 and closed in February 2024. For this funding round, we developed a new funding structure. This year two separate grants were available, known as our Foundation Award and Seed Award. Our Foundation Award supports anchoring new principal investigators in the research area of breast cancer prevention. Applications were asked to focus on Endocrine Disrupting Chemicals {EDCs) (known or suspected) and breast cancer risk. The Award will fund up to £150,000. primary applicants should be within 12 years of their PhD being awarded. Alongside the proposed funding for research, Breast Cancer UK also offered an optional career coaching programme for the duration of the grant to help support and develop the wider skills of the early career scientist. Our Seed Award is focused on chemicals and breast cancer risk. Funding can be applied flexibly and may be utilised as a top-up for a project close to completion, to nht2jn 2 cnprifir njprp nf pni ijnmpntr nr tn fi inA 2 njlnt nrniprt fnri i<pA nn chemicals and breast cancer risk. The Seed Award is limited to a total cost of £25,000. Funding decisions will be finalised early summer 2024. 12

Independent Scientific Review panel Breast Cancer UK'S Independent Scientific Review Panel provides vital expertise and scrutiny to our growing grant programme and strengthens our communicable science. The Panel, currently comprised of 14 expert members, are all independent scientists or clinicians who have knowledge across the breadth of breast cancer prevention. As well as providing peer review assessments in our grant programme, the Panel is also consulted for our in-house authored science reviews, which is critical for our Patient Information Forum Accreditation. Health Information Our health information continues to Strengthen through the publishing of several major new documents (published onto our website and linked), including our Fibre, the Gut Microbiome & Breast Cancer. Critical Windows of Susceptibility for Breast and HRT, Menopause and Breast Cancer scientific reviews. As part of our continued development of accessible health education content, we introduced health information on Life Stages, which incorporate Key Fact Sheets based on the Unborn Baby and Breast Cancer Risk. Pregnancy and Breast Cancer rn r Ri kand Menopause and Breast Cancer Risk. These new resources follow the life course and are intended to communicate how being at different stages of life can affect our breast cancer risk as well as our susceptibility to Endocrine Disrupting Chemicals. In addition to our Life Stages resource, we overhauled the Chemicals pages of our Reduce Your Risk section and introduced key fact sheets offering an accessible summary to our latest scientific reviews. These new fact sheets include Parabens 2nd breast cancer, PFAS, or per- and polyfluoroalkyl substances 2nd breast Cancer as well as a resource describing what the ￿￿L￿0&y&t0￿ is and how Endocrine Disrupting Chemicals can affect our health. We attended the London Maternity and Midwifery Festival in Febru2ry 2024, which saw high engagement with our science content, both through our leaflet- based information at our stand, and our oral presentation discussing foetal and maternal exposures to Endocrine Disrupting Chemicals. Almost 350 health professionals attended the Festival, with many taking resources from our stand to their own clinical settings. Association of Medical Research Charities Membership In January 2024, we received notification that our application to join the {AMBQ). was successful. The AMRC supports medical research charities to enhance real-world impact through research and innovation. The organisation ensures that member charities fund the highest quality research through developing guides, training and carrying out regular audits. We were delighted to be accepted as Introductory members to the organisation, which reflects and bolsters our dedication to supporting excellent world-leading research, and are now working towards Full membership. 13

Middlesex University London BREAST CANCER PREVENTION CONFERENCE On the 21st-22nd June 2023, we held our inaugural Breast Cancer Prevention Conference at Middlesex University. The aim of the conference was to bring together scientists, clinicians, students and members of other charities to collectively acknowledge, debate and discuss the latest developments in breast cancer prevention. The conference combined two critical themes of breast cancer prevention: the risks posed by environmental chemicals and how lifestyle choices can affect breast cancer risk. Over two absorbing days, world-leading clinicians, scientists, and researchers from as far afield as the US, Sweden and Switzerland discussed and debated the latest research and science around breast cancer risk factors. The conference's climax was the panel discussion, consisting of four leading scientists and clinicians. The. discussion saw a robust debate on taking the science forward to ensure it meets the criteria needed to drive regulatory and political change. Feedback from conference attendees was overwhelmingly positive, with delegates praising all aspects of the conference from the speaker line-ups and quality of the talks to the venue and organisation. Furthermore, 100% of delegates who filled in the feedback form said they were 'very likely, to attend any future conferences held by Breast Cancer UK. Public engagement on social media was also high across the two days with many positive posts on the conference. To read our 2023 conference report and view our conference video, please click here. 14

PLANS FOR THE SCIENCE PROGRAMME With the success of our last conference, we are aiming to host this as a biannual event, with the next conference due in June 2025. We intend for the focus of the event to be breast cancer primary prevention, encompassing both lifestyle and environmental factors. We seek to continue to provide a platform for scient15ts to come together, network, discuss and celebrate the latest high-quality prevention research from across the globe. Our grants programme continues to grow, and we anticipate opening a new grant funding round in autumn 2024, with closing in early spring. The focus of the funding will remain on Endocrine Disrupting Chemicals (EDCS) and breast cancer risk and will mirror the structure of the previous 2023/2024 funding round. Our science reviews continue to consolidate our understanding of breast cancer risk factors and help to deliver educational information to the public through the creation of daughter documents including key fact sheets, blogs and videos. We plan to deliver science reviews focussed on several key and emerging risk areas including phthalates" the microbiome and parabens.

OUR EDUCATION PROGRAMME

Our objectives were to: Develop educational advice for members of the public who want to know more about lifestyle and environmental risk factors for breast cancer Improve access to practical solutions that help people take direct action to reduce their risk Reach and engage more young women with our message Grow and consolidate our ambassador programme so that we help more people understand how to reduce their risk. PERSONALISED PREVENTION AND EDUCATION Our personalised approach to supporting individual prevention gained ground this year through the growth and continued improvement of our quiz and supporting interactive digital resources. More people than ever took our quiz and many are reporting back on their progress in maintaining the changes that they have put in place to reduce their risk. Our plans for the future are to continue to scale this up working closely with community and health partners to promote our practical advice. PREVENTION HUB AND EDUCATION CONTENT There were over 71,000 users of the Prevention Hub this year, almost double that of the prior year and over 3 times the Hub's 3-year target. Over 36,000 people used the Chemicals iGuide' over 12,000 used the Everyday iGuide and over 15,000 used the Quiz. About 1900 new people made a prevention plan and signed up to receive our monthly Prevention Pulse magazine. This is over 4 times higher than the prior year, thanks to additional promotion of the Quiz around Prevention Week, in June and Breast Cancer Awareness Month, in October, plus the Quiz being made more prominent on the webslte and being featured in all our outreach events and education materials. 1900 12,000 Pulse sign up 15,000 Everyday iGuide Taken the quiz 36,000 71,000 Chemical iGuide Hub users

A new version of the Quiz was also launched at the end of Breast Cancer Awareness Month. The new version captures more details about Quiz takers, such as their age, ethnicity and gender identity and this shows that the Quiz is attracting a very good representation of the UK population, by age, region and ethnicity. The new Quiz also offers people additional tailored email support for 6 months, if they want to drink less alcohol, or get more active, to reduce their risk of breast Cancer. Over 300 people chose extra support to drink less alcohol and about 350 people chose extra sUPPOrt to be more active. People are also now being encouraged to retake the Quiz at least six months apart, so that the impacts of adopting reduce your risk advice and activities can be better assessed. Over 660 people retook the Quiz this year and over 200 of them did this at least 6 months apart. PREVENTION TALKS, INSIGHTS AND FEEDBACK Demand for our education talks increased significantly this year. To 5UPPOrt this demand and to enable wider access to our life changing prevention education, we will develop a scalable outreach education programme to take our talks and education to people across the country. PREVENTION WEEK 2023 Age-related breast cancer risk: During Prevention Week 2023, we focused on raising awareness of the significant increase in breast cancer risk among women over 40. Representing over 95% of new cases, this demographic highlights the importance of targeted prevention efforts. To address this significant issue, we developed a comprehensive campaign to educate the public about the age-related factors contributing to breast cancer risk and empowering individuals to adopt proactive measures for risk reduction. By highlighting a different risk factor each day, we emphasised the creation of sustainable healthy habits as a cornerstone of prevention. We introduced a downloadable Weekly Wellness Planner to SUPPOrt people adopt healthier lifestyles. This practical tool empowers users to track progress towards their health goals, such as increasing physical activity, reducing alcohol consumption, or improving nutrition. BCAM 2023 Move More, Raise More, Reduce Risk: Building upon the success of the previous year, our Breast Cancer Awareness Month campaign in 2023 once again highlighted the powerful link between physical activity and breast cancer prevention. Our signature 30-Day Challenge encouraged participants to incorporate daily exercise into their routines, fostering healthy habits while raising vital funds. 18

To further support our prevention community, we introduced the B Well Club, a membership programme dedicated to prevention. Members received exclusive wellnes5 advice, recipes, and exercise tips to empower them to make lasting lifestyle changes. By combining fundraising with education and support, we aimed to create a comprehensive approach to reducing breast cancer risk. PLANS FOR OUR EDUCATIONAL PROGRAMME Next year we plan to make our prevention education even more accessible through introducing a high quality education outreach programme to complement our digital offer. The Quiz will be integrated into the outreach programme and will continue to evolve with tailored email support for people who want to improve lifestyle risk factors for breast cancer. By nurturing relationships with the many people who take the quiz, and analysing their responses, we will implement research measures to help us understand and evaluate the benefits our quiz and tailored education have in reducing people's risk over time. This will give us practical insights into the impact of our prevention work. Prevention Saves Lives Start your prevention journey with ow qui ulz and lannor. Start¢)wz > "Lovp thls.- Really iTrked the prev8ntlon plarL_ Very helpful and important for me and ralsing my two tiny hurnar￿, 5kof owt(yps Chooso preventio C￿rinthe1utU1¢. E¥￿ry￿e hassome riskofgetNngte3St te*th￿aN 19

OUR ADVOCACY PROGRAMME

Our objectives for the last year were to: Encourage a preventative approach by campaigning to improve legislation and public he21th policy which helps to promote the primary prevention of breast cancer. Work at UK levels for policy and regulatory changes that help to protect against breast cancer. Raise the profile of our key messages amongst political decision makers by establishing a network of activists to help us make our message heard. OUR CAMPAIGNING Our campaigning objectives remained consistent into our 23/24 year with a main focus on. Promoting preventative approaches to breast cancer and more broadly prevention being put at the centre of healthcare policy. Work to bring about policy changes at all levels of government that promote a preventative approach in health policy. Principally, the scrapping of the proposed Major Conditions Strategy and the return of a standalone Cancer Strategy. Advocate for a precautionary principle approach in chemicals regulation and the publication of a Chemicals Strategy. We put our case to top officials in the Department for Environment Food and Rural Affairs. In collaboration with other organisations, we advocated to the Government to keep high regulatory standards and not diverge from the European Union's established regulatory system and EU REACH. In preparation for the expected general election, we reached out to those in opposition and identified key alignments in our policy priorities on cancer prevention. We were proud to produce our first Manifesto for Breast Cancer Prevention, merging our scientific knowledge with our policy expertise on breast cancer prevention into a single document. Work on this began in the period covered by this report. ADVOCACY ANDCAMPAIGNING This year we led on a number of consultation submissions including on the Regulatory Management Options Analysis for bisphenols where we highlighted the need for a greater focus on the cocktail effect on human health through exposure to multiple chemicals in our daily lives. While we continued to point out to the Government th2t the UK is falling well behind European countries such as Germany who continue to pursue more stringent restrictions on the use and distribution of bisphenols, it was frustratingly clear that the then Government was not persuaded on the urgency to address either point. 21

Given the limited progress with the Government's regulatory and policy developments on chemical exposures, thanks to the support of the Savitri Trustee, we collaborated with our partners in the NGO working group on hazardous chemica15 to develop a bespoke public awareness campaign on the impact of harmful chemicals on our health including on our breast cancer risk. This work will feed into Breast Cancer UK'S mobilisation campaign. We continued to develop constructive relationships with the Department for Environment Food and Rural Affairs (Defra) and the Department for Health and Social Care (DHSC). We also engaged directly with Dr Philippa Whitford, then MP and breast cancer surgeon and the then MP for Hitchin and Harpenden, Bim Afolami who provided a message of support at our breast cancer prevention conference and also supported our cause by sharing our quiz with his constituents. Additionally, we wrote to. Victoria Atkins MP (then Secretary of State for Health and Social Care) Rishi Sunak MP (the Prime Minister) Steve Barclay (then Secretary of State for Health and Social Care} Rebecca Pow (then Parliamentary Under-secretary of State at the Department for Environment, Food and Rural Affairs, with responsibility for chemicals policy) COLLABORATION Our size as an organisation, the complexity of the policy areas that we work within 2nd the difficult politlC21 landscape that characterised this period made collaboration an absolutely crucial part of our work. We continue to be a driving force behind the NGO working group for hazardous chemicals which brings together several organisations with interests in chemical regulation. A sub-group was formed from this, the 'Health sub-committee,, which looks specifically at the human health implications of exposure to harmful chemicals. In addition, we have strong links with the EDC-Free Europe coalition and the European Movement with whom we share information and ideas around alignment with EU REACH (the European Regulatory System for Chemicals). We have also continued to build alliances with organisations with whom we share policy priorities including CH EMTrust, Animal Free Research, the Women's Environmental Network, the Wildlife and Countryside Links and the Alcohol Health Alliance. NEXT STEPS Our priority looking ahead is to launch our manifesto alongside the general election, giving us a basis from which to influence policy development on breast cancer prevention. We will target key MPS, Peers and policy-makers who we believe should be engaging with our work. 22

We will continue to nurture our existing partnerships and recognise that these are vital in making sure that we are around the table for key policy discussions. However, we also recognise that there are other organisations, particularly health charities, who may be campaigning for similar outcomes to ourselves, such as improving the public's eating, drinking or buying habits and we will be actively looking to partner with those organisations. As we come towards the end of the existing Public Affairs Strategy, we will embark on new planning work to set out a robust 3-year plan for our advocacy and campaigning work in the years ahead. We will be looking to build a plan that engages more closely with our supporters, empowering them to help drive the change needed to make breast cancer prevention a policy priority. ca EST EAST CANCER PREVENTION 23

OUR GENEROUS SUPPORTERS

This was a year of continued growth for our fundraising team. A year in which we set the foundations for our long-term ambitions. An ambition to take our income from just over £IM to over £4M within the next 5 years. Backed by an army of committed supporters who are joining our mission to put prevention at the top of the breast cancer debate. We thank them all for their invaluable support. REGULAR GIVING (THE B WELL CLUB) We developed and launched our new monthly regular giving offer - The B Well Club. Each month we send our wonderful members fun and practical wellness advice backed by science. We have curated recipes, exercises, healthy habits and much more to help people make small changes to their daily lives to improve their overall health and reduce their breast cancer risk. reas cancer uk. •J Hello, <>l It's time to spring into life .1 Celthathys a￿ in tyder! We've rtwde it thr¢W￿ the LMg, dark i)s of wirter, aTrJ iv5 finally to Eet cth5th and eftioy tevry at ￿le V+ith nature. If ￿'ve shbed away frcln riding y￿r th.ke or golng on Yfti&s tecause Gf you're Tr)t alore. &Jt wth the 5WJ s40￿Y starting to retLYn, it's rErfect t7￿ to get back out tse aEain. Sprfne ts a seawi of ¥tfvatSrn, w￿ther St's eatlng tetter, maklng for exercF5e, ftmdraisir¢> or tyi"nE yow hand at that thing you've putting off a ￿lIe, hit the activate buttcn! P.S. FIcvJEf5 arn't the thi￿ tl4t ￿ 5prv)g into life th15 seas(￿. 25

COMMUNITY AND EVENTS FUNDRAISING People fundraising for us has long been the bedrock of our fundraising programme and we're so grateful and thankful for their fantastic ongoing support. This year 622 people ran event5 for us raising £480,504.84 an average of £772 per fundraiser. Alongside this several supporters took part in organised events to support our work this included: Battle Cancer: We had 42 participants who raised £22,092.24 Kilt walk: We had 44 participants who raised £14,388.75 Skydiving: We had 24 participants who raised £33,990.49. HERE'S SOME HIGHLIGHTS FROM OUR WONDERFUL FUNDRAISERS: Thank you to Ivan Mond, a 90-year-old skydiver and his family who raised £8,576. We ensured they had impactful media coverage during April 2023 here. Thank you to Ashley and Oliver from Northamptonshire who trekked to Everest Base Camp in August 2023, before attempting to climb and summit a nearby peak - Imja Tse16,160m, 20,200 ft). They raised £5,916.63 h Thank you to brothers Alex and Olly from Derbyshire who took part in the Peak District Ultra Marathon at the start of October 2023 as their mum had recently been diagnosed with breast cancer, they raised £7,187 here. Thank you to James Roden and his colleagues from the RAF Lechlade who took part in a pedalo challenge along the Thames in July 2023 and raised £14,041.26 here. Thank you to Jessica Allan from the West Midlands and her sister Emma who organised a 20-mile sponsored walk at the end of March 2023 to mark 20 years since their mum Helen Brayn passed away, they raised £5,088.75 including gift aid on JustGiving here. We thank Karen Whitehead who, in June 2023, shaved her head in solidarity with a friend who is currently going through breast cancer, raising £7,196 here. Thank you to Nick White and his team TMAAT (Three Men and a Tent) who raised £6,283 as they took part in a cycling challenge from London to Athens in May and June 2023 h We thank Peter Mackenzie from Cheshire who, in August 2023, took on his second challenge for Breast Cancer UK. He played 250 holes of golf in 24 hours and raised £12,712.15 here. Thank you to James Saunderson and 5 teams from The Unit Gym and Fitness who took part in Battle Cancer Scotland in June 2023. James's wife Hazel was being treated for Breast cancer. The group raised £15,052.78 here. 26

Thank you to Gavin O'Rourke from London who took part in the London Marathon in April 2023, his wife has previously had breast cancer. He raised £5,012.13 here. Thank you to Hannah Blaber and friends from Knowle Tennis Club in Bristol who held a 12-hour Tennis Marathon in May 2023 in memory of their friend Malgo. They raised £5,500.471 Breast¥ ' 27

PHILANTHROPIC GIVING We are hugely grateful to those supporters who generously pledged their gifts through Wills and donated in memory of a loved one. These gifts have enabled us to make significant investments in our scientific research and our education programmes both of which have grown thanks to the highly valuable support of these donors. Our two largest legacy gifts were from Mr Deryck Anthony Nott and from Mrs Jean Mary Hastings. We plan to continue to nurture and develop rewarding relationships with donors whose dedication to our mission and our cause is key to strengthening and growing our impact. We wholeheartedly thank all of our valuable donors for choosing to support our charity. We were extremely thankful to receive a number of other large in memory gifts from Mary Edkins, Amanda Symes and Ailsa Thomas. CORPORATE PARTNERSHIPS We were supported by a wide range of wonderful businesses and their great teams who do amazing things for us, from putting on golf days, throwing themselves out of plane5, to donating a percentage of profits from the sale of products. We want to thank all of the businesses and organisations who generously supported us this year. Some highlights: fljmhpr< A92jn<t f2nrpr r2j<prl FA 747 In tnt21 frnni nrtnhpr tn nprpmhpr. We received £15,000 from Morelli Group Ltd who enjoyed a golf day organised by the staff at Morelli Group in memory of one of the employee's sisters - This was our biggest staff fundraising total from one event last year. For the second year in a row, the staff at Olayan Group raised just under £10,000 from their fundraising run for Breast Cancer UK. Our plan for the future is to continue to build long-term business support from companies and organisations that share our values and passion for our cause. CAC Al&Yth20J4 I/K £674700 28

FINANCIAL REVIEW

The Directors present their report with financial statements of the Company for the year ended 31st March 2024. In preparing this report the Directors have taken advantage of some of the special exemptions applicable to small companies. PRINCIPAL FUNDING SOURCES Total funds raised this year were £1,537,624 and saw income from donations {excluding legacy gifts) growing by 33% on last year (£1,143,570 up from £859,247). Total funds shows 2 generally sustained income generation compared to last year's total funds raised of £1,585,839. This demonstrates the continuing steady returns of our effort to grow the profile and outputs of our work. The team continued to manage risk through routine risk assessments and regular budget tracking and forecasting. Improving access to our messaging and education to wider and more diverse audiences continues to be our priority. We approached the development of our advice and awareness campaign through testing 2nd learning from audience responses. We made a significant investment in relationship management systems which has enabled us to take a more informed and targeted approach to nurturing relationships with our supporters and audiences. The balance of effective risk management and innovation continues to drive the growth of our supporter community and the growth of our organisation. Our largest source of income came from community fundraising £540,872 which was made up of individual fundraising £424,442, and fundraising by educational facilities, sports clubs and other clubs/societies £116,430. This was followed by income from legacy giving of £321,407. The next highest sources of income were from in memory giving £212,850, and individual giving £93,760. We received £114,722 in fundraising from staff in corporate organisations. Finally, we continue to partner with smaller companies and individuals too and would particularly like to thank them for their ongoing support. Corporate donations including cause-related amounted to £62,159. CHARITABLE EXPENDITURE We continued to manage spending cautiously due to rising concerns relating to the cost-of-living crisis. We took steps to minimise costs and overheads while ensuring we maximised funds spent on our charitable cause. As with last year, we incorporated in our expenditure targets, strategic areas of investment to help progress our growth and impact in line with the objectives of our strategic plan. We closely reviewed investments quarter by quarter and assessed risk, as part of investment decisions. This year, we spent 74/ (855,555) on charitable activities and 26/. (304,456) on raising funds. 30

Our most significant investment was in our scientific research programme {£397,909) followed by our education programme {£234,8041 as we continued to increase activities to deliver accessible digital and print education content. RESERVES POLICY Purpose of the Reserves The charity holds reserves to provide funding to support the continuation of the charitable aims and objectives and the ability to meet financial commitments in the event of a significant unforeseen reduction in income or increase in operational costs. Level of Reserves The level of reserves is set by considering the uncertain nature of the charity's income (which relies entirely on donations, legacies and grants) and the recurrent expenditure and financial commitments the charity has. The charity has limited overheads arising from accommodation as we do not have a central off ice space. Hence our main financial commitments and running costs arise from staffing and research grants. Desigiiated Fund5 The charity is committed to funding research into the chemical and environmental causes of breast cancer. Research grant applications from independent academic institutions are considered periodically and approved at the Board level. Designated funds represent funds approved by the Board for future spending on research grants and other projects that aim to deliver our charitable objectives. The level of designated funds is updated throughout the year to reflect the amount of funds set aside for future projects until the funds are either committed to a project or a decision is made to un-designate them if a project does not go ahead. Free Reserves Breast Cancer UK is committed to a programme of activity that meets our charitable objectives. Given the uncertain nature of legacies, budgets are prepared on the assumption that only in cases where we have already been formally notified, are they included in income. As a result, sudden large legacies or donations that are received during the financial year can result in reserves being held that are more than Breast Cancer UK'S reserves policy {free reserves) after allowing for designated funds. To help us address this, our business plans now include a priority list of research and education projects which align with our strategic priorities and the impact that we want to achieve. Thus, excess legacies or unexpectedly large donations will be directed promptly to these projects. We are continuing to monitor legacy income for trends with 2 view to assessing the feasibility of including projections in future income target setting. 31

ALltliorily.. MoiiiLoriiig arid Reportiiig Ongoing monitoring of the reserves is undertaken during the year by the CEO, Finance Director and Finance Trustee. We report the reserve position including how funds are allocated to the Audit Risk and Resources Committee. Reserve Policy Review The Reserves Policy is reviewed annually by the Audit, Risk and Resources Committee in February and approved by the Board of Trustees in March, reviewing in detail the reserve position and taking into account prevailing conditions in the charity sector and short-term and medium-term plans for the charity. At the Board meeting on 27th March 2024, the Trustees determined that £313,940 should be held in emergency reserve. This represents 70°A of our most vulnerable income stream and was calculated based on risk in the reduction of income in those income streams. The total reserve level is sufficient to allow for the financial implications of a downturn in income or the need to significantly increase operational expenditure. General unrestricted funds at year-end were £2,081,921 of which £712,782 were designated funds, including £172,380 for science grants, £200,000 for the Science Foundation Award, £36,000 for the Breast Cancer Prevention Conference and £304,402 for other charity projects. Net of designated funds and our emergency reserve of £313,940, excess free reserves were £1,055,199. We were pleased to find that the negative impact on income from the cost-of- living crisis and the war in Ukraine did not occur this year, with steady income growth occurring throughout the year. Despite this, we recognise the continued uncertainty and have therefore maintained a precautionary approach to ensure we can weather the storm of any financial crisis ahead. RESULTS AND CLOSING POSITION The charity's income exceeded expenditure this year by £377,613 . This surplus was welcome given the continuing investments we have made to grow our science and education programmes this year. Our total income reduced by £33, 661 from 2023. Our total expenditure was 4% under budget. Total income exceeded our annual budget target by £709,664 including legacy and grants. In light of the ongoing cost of living crisis, we took a cautious approach to our target setting whilst increasing our outputs and contents. This along with some generous unexpected legacy gifts will explain the excess in income over targets. Given our initial projection of £426,835 in planned deficit at 2023/24-ye2r end, our very positive closing is a testament to our investment and risk management policy, yielding extremely favourable returns and stability for our charity. We enter the year ahead with confidence to Stay on track to grow sustainably and achieve impact for our beneficiaries. 32

STRUCTURE GOVERNANCE AND MANAGEMENT

STRUCTURE Breast Cancer UK is a charitable company limited by guarantee (registration number 073484081, registered on the 8th of November 2010 2nd registered as a charity on the 15th of August 2001 (registered charity number 11388661. The company was established under the Memorandum of Association, which established the objects and powers of the charitable company. In the event of the company being wound up, members are required to contribute an amount not exceeding £10. Our charitable objectives are as follows: l.to advance health and save lives by encouraging a preventative approach to breast cancer 2.to educate and raise awareness of the preventable risk factors for breast cancer and provide practical information to help people reduce their risk. and 3.to support scientific research that helps us to understand and address the preventable risk factors for breast cancer. GOVERNANCE The Directors of the Company, who are listed on the last page of this report are also charity trustees for the purposes of charity law and under the Company's articles are known as members of the Board of Trustees. All members of the Board of Trustees give their time voluntsrily and receive no benefits from the charity. Any expenses reclaimed from the charity are set out in note 3 to the account5. Several trustees have suffered from breast cancer or are close to people who have suffered from the disease. They use their own experience in this area to assist the charity. In recruiting Trustees, the members seek to ensure the charity benefits from a broad range of different skills and expertise. Skills 2nd expertise represented on the board include science and policy, medicine, cancer services, governance, law, accountancy, fundraising, PR, business management and IT. In the event of skills or individuals being lost due to retirements or resignations, the charity advertises for specific skills and interviews are carried out to ensure the most appropriate appointments are made. This year we were sad to say goodbye to Britta Stordal, Nichole Taske and Charlie Winstanley. Britta Stordal who served as Deputy Chair stood down at the end of her second term on 23rd of September 2024. Nichole who had served as Trustee since 11 December 2019, stood down on 19th September 2024 and Charlie who served as Trustee since 30 June 2022 stood down on 5th June 2024. Both Nichole and Charlie resigned due to increasing work commitments. We were delighted to welcome four new Trustees to the board, Nazia Tingay, Lotte Spencer, Silvy Mardiguian and Beezy Marsh who each who joined the board on Ilth March 2024. 34

Board of Trustees Audit, Risk and Resources Committee Science and Public Affairs Committee STAFF Breast Cancer UK'S staff are our greatest asset and we are committed to supporting every employee to achieve their potential and achieve personal goals which in turn will assist the organisation to achieve its objectives. Since 2020 and in an effort to remain competitive, retain staff and attract talent, we have continuously reviewed and evolved the team's functions, structure, benefits and remuneration. This year we continued to expand our team across work areas to reinforce resourcing and expertise. We conduct regular reviews of our salaries and benefits package and we periodically consult with colleagues on work conditions, ways of working and personal satisfaction to inform the continued evolution of our unique organisational culture and values. BREAST CANCER UK ORGANOGRAM RISK MANAGEMENT A risk register is established. Risk management sits with the CEO and ownership sit5 Wlth Specific Committees and the Board. The Committees of the Board of Trustees and the Board itself reviews the Risk Register at each meeting and it is updated regularly. Mitigating actions are considered and reviewed regularly. All policie5 and processes are under rolling review to ensure we are compliant with regulation. 35

STATEMENT OF PUBLIC BENEFIT The Trustees confirm that they have complied with the duty in Section 17 of the Charities Act 2011 to have regard to the Charity Commission's General Guidance on public benefit. Our charitable objectives are enshrined in our Memorandum of Association and Trustees to ensure that the charity's activities are carried out for the public benefit. In July, these articles were formally amended with a special resolution passed to amend our 'objects' clause through our three new strategic approaches: to advance health and save lives by encouraging a preventative approach to breast cancer to educate and raise awareness of the preventable risk factors for breast cancer and provide practical information to help people reduce their risk to support scientific research that helps us to understand and address the preventable risk factors for breast cancer. This report allows us to show how our charitable funds are spent and the impact that this has on those who access our information or use our services, as well as on the wider challenge to reduce breast cancer incidence rates. By Order of the Board Ruth Freeborough (Chair and Director of the Board of Trustees) Breast Cancer UK Limited 211212024 36

STATEMENT OF TRUSTEES RESPONSIBILITIES FOR THE YEAR ENDED 31 MARCH 2024 The trustees (who are also the directors of Breast Cancer UK Limited for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statement5 in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to select suitable accounting policies and then apply them consistently observe the methods and principles in the Charity SORP make judgements and estimates that are reasonable and prudent prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business. The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. 37

INDEPENDENT AUDITOR ʼS REPORT TO THE MEMBERS OF BREAST CANCER UK LIMITED

Opinion

We have audited the financial statements of Breast Cancer UK Limited (the ‘Charity’) for the year ended 31 March 2024 which comprise the Statement of Financial Activities, the Balance Sheet, statement of cash flows and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Opinion on financial statements

In our opinion the financial statements:

• give a true and fair view of the state of the charitable company’s affairs as at 31 March 2024 and of its income and expenditure for the year then ended:

• have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

• have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditorʼs responsibilities for the audit of the financial statements section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRCʼs Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our auditorʼs report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

38

INDEPENDENT AUDITOR ʼS REPORT TO THE MEMBERS OF BREAST CANCER UK LIMITED Opinion on other matter prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

• the information given in the trustees’ report (incorporating the directors’ report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and

• the trustees’ report (incorporating the directors’ report) has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the Charity and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ Annual Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

• adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or

• the financial statements are not in agreement with the accounting records and returns; or

• certain disclosures of trustees’ remuneration specified by law are not made; or

• we have not received all the information and explanations we require for our audit.

Responsibilities of the trustees

As explained more fully in the Trustees’ Responsibilities Statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the Charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the Charity or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorʼs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud are set out below.

39

INDEPENDENT AUDITOR ʼS REPORT TO THE MEMBERS OF BREAST CANCER UK LIMITED

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

• We enquired of management, which included obtaining and reviewing supporting documentation, concerning the charity's policies and procedures relating to:

• identifying, evaluating, and complying with laws and regulations and whether they were aware of any instances of non-compliance;

• Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected, or alleged fraud;

• The internal controls established to mitigate risks related to fraud or non-compliance with laws and regulations.

• We inspected the minutes of meetings of those charged with governance.

• We obtained an understanding of the legal and regulatory framework that the charity operates in, focusing on those laws and regulations that had a material effect on the financial statements or that had a fundamental effect on the operations of the charity from our professional and sector experience.

• We reviewed the financial statement disclosures and tested these to supporting documentation to assess compliance with applicable laws and regulations.

• We performed analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud.

• In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments, assessed whether the judgements made in making accounting estimates are indicative of a potential bias and tested significant transactions that are unusual or those outside the normal course of business.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Councilʼs website at: [www.frc.org.uk/auditorsresponsibilities]. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charity’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity’s members as a body, for our audit work, for this report, or for the opinions we have formed.

12/12/2024

……………………………….

Anthony Epton (Senior Statutory Auditor) for and on behalf of Goldwins Limited Statutory Auditor Chartered Accountants 75 Maygrove Road West Hampstead London NW6 2EG

40

FINANCIAL STATEMENTS

Breast Cancer UK Limlted Statement of financial activlties lincorporaiing an income and expenditure account) For the ear ended 31 March 2024 2024 2023 Unrestricted Resiricted Fund Fund Total Fund Unresiricted Restricted Fund Fund Total Fund Note Income from: Donations and legacies Charitable activities Investments 1,443,8S9 21.118 1,464,977 1,433,844 83 14,471 137.441 1.S71,28S 83 14.471 72.647 72.647 Toial Income 1,516,506 21,118 1,537,624 1,448,398 137,441 1.585,839 Expendlture on.. Raising funds Charitable acriviiles Campaign costs Education costs Science costs 304,456 304.456 205,476 205,476 220.392 213,672 297,909 2.450 222,842 234,804 397,909 141,996 185,993 137,235 22,5SO 18,480 164,546 204,473 137,235 i 00,000 Total expentllture 1,036,429 123,582 1,160,01 670,700 41.030 711,730 Net income I (expenditure) for the year 480.077 (102.4641 377.613 777,698 96.411 874,109 Tiansfers between funds 2,994 (2.9941 Net income I IcxpenditLtr¢) before other recognised gains and losses 480,077 1102,4641 377.613 780,692 93.417 874,109 Net movement in funds 480,077 1102,4641 377,613 780,692 93,417 874,109 Reconciliation of funds- Total funds broughr fO￿ard .601.844 151.389 1,753,233 821,152 5 7.972 879,124 Toial funds carried forward 2.081.921 48.925 2.130.846 1.601 ,844 ISl.389 1.753.233 All of the above results are derlved from conilnulng acrl¥lties. There were no oihei recognlsed galns or losses other than those stated above. Movements in funds are disclosed In Note to the flnancial statemenis. 42

Breast Cancer UK Limited Balance sheet As at 31 March 2024 Com an no. 07348408 2024 2023 Note Current assets: Debtors Cash at bank and in hand 191,082 2.251,559 38,746 ,932,025 2.442,641 ,970,771 Liabilities.. Creditors.. amounts falling due within one year 12 (185,371) 1109,1101 Net current assets I Iliabilitiesl 2,257,270 1.861,661 Total assets less current liabilities 2,257,270 1,861,661 Creditors.. amounts falling due after one year 13 (126.424) 1108,428) Total net assets I Iliabilitiesl 2,130,846 1,753,233 The funds of the charlty.. Restricted income funds Unrestricted income funds.. Designated funds General funds 48.925 151,389 712,782 ,369,139 444,000 1,157,844 Total unrestricted funds 2,081,921 1,601,844 Total charity funds 2,130,846 1,753,233 The financial statements have been prepared in accordance with the special provisions for small companies under Partl S of the Companles Act 2006. Approved by the trustees on 02/12/24 and si9ned on their behalf by ALTL Ruth Freeborough Trustee 43

Breast Cancer UK Limited Statement of cash flows For the ear ended 31 March 2024 Note 2024 2023 Cash flows from operating actlvitles Net cash provlded by I (used Inl operatlng activities 246,887 769,964 Investing activities Investment income received 72,647 14,471 Net cash generated from invesring activities 72,647 14,471 Net cash provlded by I (used Inl financing activities Change in cash and cash equivalents in the year 319,534 784,435 Cash and cash equivalents at the beginning of the year ,932.025 1.147,590 Cash and cash equivalents at the end of the year 2,251.559 1,932,025

Breast Cancer UK Limited Notes to the financial statements For ihe ear ended 31 March 2024 Accounting policies Charity information Breast Cancer UK Limited is a private company limited by guarantee incorporated in England and Wales. The registered office is The Union Building, 51-59 Rose Lane. No¥wich. Noifolk, NRI 18Y, England. a) Basis of preparation The financial statements have been prepared in accordance wilh Accounring and Reponing by Charities.. Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 102 effective l January 20191- (Charities SORP FRS 1021 and the Companie5 Act 2006. The charirable company meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at hi5toriial 1051 or transaction value unle55 Otherwise stated in the relevant accounting policy or note. bl Going concern The trustees consider that there are no material uncertainties about the charitable company's ability to continue as a 9oing concern. The trustees do not consider that there are any source5 of estimation uncertainly at the reporting date that have a significant risk of causing a material adjustment 10 the carrying amount5 of a55et5 and liabilitie5 Wlthin the next reporting peiiod. cl Income Income is recognised when rhe charity has eniitlement ro the funds, any performance condiiions attached to the income have been met, it is probable that the income will be received and that the amount can be measured reliablv. Income from government and other 9rants, whether 'capttal' grant5 or 'revenue' grant5. 15 recogni5ed when rhe charity has entitlement to rhe funds. any performance conditions atiached io ihe grants have been met. it is probable thar the income will be received and the amount can be measured reliably and is not deferred. For legacies, entitlement is taken a5 the earlier of the date on which either.. the charity is aware that probate has been granted, the esiate has been finalised and notification has been made by the execuLvrls1 ILTr the chilflly Lhal a Lli51ributlDn will be made, ur when tjisiribuiion 15 ieceiveLt fium the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the execuior's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of rhe grantin9 of probate. and the criteria for income recognition have not been met, then the legacy is a treated as a contingent asset and disclosed if material. Incomo r•coivod in advanc• of tho provision of a gpqcifiad g¥trvic• is d•f•rrqd until tho crit4ria for income recognition are met. dl Donations of gifts. seNices and facilities Donated professional services and donated facilities are recognised as income when the charity has conirol over the item or received rhe service. any conditions associated with the donaiion have been met. the receipt of economic beneflr from the use by the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP IFRS 1021, volunteer rime is noi recognised so iefer to the trustees, annual report for more information about their On receipi. donated gifrs. professional services and donated facillties are recognised on the basis of the value of ihe gifi to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefii on (he open market- a corresponding amount 15 then recogni5ed in expenditure in the period of receipt. e) Interest receivable Inieresi on funds helij ot) deposii Is included when receivable and the amount can be measured reliably by the charity,. this is normally upon notification of the interest paid or payable by the bank. D Fund accounting Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund. Unrestricted funds are donations and other incoming resources received or generaied for the charitable purposes. Designared funds are unrestricred funds earmarked by the trustees for particular purpose5. 45

Breast Cancer UK Limited Notes to the financial statements For ihe ear ended 31 March 2024 Accounting policies Icontinuedl g) Expenditure and irrecoverable VAT Expenditure is reco9nised once there is a legal or constructive obligation to make a payment to a third party. it is probable that settlement will be Teqvired and the amount of the obligation can be measured reliably. Expenditure is classified under the following activity headings.. Costs of raising funds relate to the costs incurred by the charitable company in inducing third parties to make voluntary contributions to it, as well as the cost of any activities with a fundraising purp05e Fxp&nditiJrp nn rhArltAblp Artiviti•s incliJdp% the ro%ts of dglivgring services, IAnd•rtaken to fLJriher the purposes of the charity and their a5socialed support Costs. Oiher expenditure represents those irems not falling into any other heading Irrecoverable VAT is charged as a cost against the activtty for which the expenditure was incurred. h} Allocatlon of support costs Resources expended are allocated to the pariicular activity where the cost relares direcrly to rhai activity. However, the cost of overall direction admintstration of each activity, comprising the salary and overhead costs of the central function. is apportioned on the basis which are an estimate, based on staff c05t. of the amount attributable to each activtty. Where information about the aim5. objectives and projects of the charity is provided to potential beneficiaries, the costs associated with this publicity are allocated to charitable expenditure. 11 Operating leases Rental charges are char9ed on a straight line basis over the term of rhe lease. j) Tangible fixed asset5 Items of equipment are capitalised where the purchase price exceeds £ 1.000. Depreciation costs are allocated to activities on tht basis of the use of the ielated assets in those activitles. Assets are reviewed fur imP<iirtnEnl if iiicum5t¢ince5 indiLaie thEii carrying value Wn¢ay exceed theii net ie&iliSdble value and value in use. Depreciation is provided at rates calculated to write down the cost of each asset to Its estimated residual value over its expected useful life. kl Debtors Trade and other debtors are recognised ar the settlement amount due after any trade discount offered. Prepayments are valued ai the amount prepaid net of any trade discounis due. 11 Cash at bank and In hand Cash at bank and cash in hand includes cash and short term highly liquid investmenls with a short maiurity of Ehree months or less from the date of acquisition or opening of ihe deposii or similar account. Cash balances exclude any funds held on behalf of service users. ml Creditors and provision5 Creditors and provisions are recognised where the charity has a present obligation resuliing from a past event that will probably result in the transfer of fund5 to a third party and the amount (Jue to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due. nl Financial instruments The charity only has financial asset5 and financial liabilities of a kind that qualify as basic financial insiruments. Basic financbal instruments are inirially recognised ar iransaciion value and subsequently measured at iheir settlement value with the exception of bank loans which are subsequently measured at amort15ed cost using the effective interest fflethod. ol Pensions Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due. 46

Breast Cancer UK Limited Notes to the financial statements For ihe ear ended 31 March 2024 2 Income from donation5 and legacies 2024 Total Unrestricted Restrlcted 2023 Toi31 Unrestricted Restiicred DonatlOn5 and gift5 Legacies receivable Grants .122,452 321.407 21,118 1,143,570 321.407 776.806 657.038 82,441 859,247 657,038 55.000 55,000 .443,859 21,118 1,464.977 1,433,844 137,441 1,571,285 3 Income from charitable activities 2024 Total Unrestricted Restrlcted 2023 Toial Unrestricted Restrlcred Ticket sales 83 83 Total income from charitable 83 83 4 Income from investment5 2024 Total Unrestrlcted Restricted 2023 Toial Unrestrlcted Restricted Dep05ir account interest 72,647 72.647 14,471 14,471 72,647 72,647 14.471 14,471 47

Breast Cancer UK Llmited Notes io rhe financial siatements For the ear ended 31 March 2024 5 Analysis of expenditure C05t of Charitable activities ralslng Campaign Education Stience funds costs costs cosis Support cosrs 2024 Toial 2023 Toial Staff costs INote 7) Consuliancy lees Promoiional activittes Subscripiions and memberships Trainin9 COSt5 Cranrs Recruitment costs Prevention hub Klck Start a Chemicals Breast Cancer in Men Donor enrry and plaiform fees Staff welfare Travel, accommod3tlon and meeilngs Insurance Website and IT Printing, postage and stationery Sundries Ttlephone Governance cost5 Bank Charges Audii fees Accountancy Fees Legal and professional fees Trustee5' meetings and training 1 $0,260 145,839 139,840 108,015 129.428 13,501 16,758 3,798 5.146 31.032 6,948 33,949 1.234 1.340 673,382 39,203 74,689 6,800 12.356 199,272 7,913 462,695 24,365 29.949 16.205 4.077 1.039 9.666 204 22.550 18.480 19.191 5.000 12.771 2.066 58.946 2.881 2,712 3,768 iio 2,760 3,384 20 1.041 8.689 2,242 65 199,272 3.103 1.560 2,003 321 926 1,330 1,330 34,968 6.135 24.991 534 53,658 2.412 2.647 3,240 34.968 6.135 16.997 534 53.658 608 2.647 3.240 932 3.008 3,103 951 1.804 49 49 7.200 7,200 2.592 2,592 4,580 4,580 2.060 2,060 157.014 171,683 349.153 245.530 1.160.011 61.410 58,884 45.483 1229,0491 4.418 4,237 3.273 116,4811 6.600 5.354 2.213 888 236.631 63.272 4.553 711.730 SLSPPOrt costs Governance costs Toral expendiiure 2024 304.456 222,842 234.804 397,909 1.160.011 The total expend5ture £1.036.429 was unrestricted 12023_ £670.700) and £123.582 12023.. £41.030) was restrlcted. Analysis of expenditure Iprior yearl Cost of Charitable attivities raisin9 Campaign Education Science funds costs costs costs Support costs 2023 Total Staff costs INote 7) Consultancy lees Promoiional actlvities Subscriptions and rnembtrships Trainin9 Costs Grants Recruitment costs Preveniion hub Kick Start a Chemicals Breast Cancer in Men Donor entry and platform fees Staff welfare Travel, accommodation and meeilngs Insurance Website and IT Prlnting, postage and statlonerv Sundries Telephone Finance costs Governance costs Audit fees Accouniancy Fees Legal and professional fees Tru5tees' meeilngs and tfalnlllg 109.442 600 20.660 2.286 422 82.415 104,867 596 16.781 2.524 3,985 9,211 1,074 119 936 84.032 600 2.780 81.939 5.788 462,695 24.365 29,949 16,205 4,077 1,039 9,666 204 22,550 18.480 19,191 5.000 12,771 2,066 58,946 2.881 2.712 3.768 3.634 2.336 264 1.039 1.053 3.369 2.782 96 22.550 2.462 108 18,480 19.191 5.000 7.351 2.066 58.946 724 2.712 3.768 1.569 2,371 620 860 2.152 6.600 5.354 2.213 6,600 5.354 2,213 888 159.691 122.664 146,851 90.633 191.891 42.021 38.119 53,858 42.838 1176,8361 3.764 3.763 3,764 3.764 115,0551 205,476 164,546 204,473 137,235 711,730 Support £os¢s Governance costs Total expenditure 2023 711,730 48

Breast Cancer UK Limited Notes to the financial 5taternent5 For the year ended 31 March 2024 Net incoming resources for the year This is staEed after charging I crediting.. 2024 2023 Auditors. remuneration (excluding VAT).. Audit 6,000 5.500 Analysis of staff costs. trustee remuneration and expenses, and the cost of key management personnel Staff costs were as follows.. 2024 2023 Salaries and wages Social security cosrs Employer's contribution ro defined pension schemes Freelance staffs 579.127 44,300 20,010 29,945 419,754 29,517 13.424 673,382 462.695 The number of employees whose annual remuneration was more than £60,000 is as follows- 2024 2023 Numbor Number £70,001 £80,000 £8n.ooi-£on.ono The total employee benefits including pension and national insurance contributions of the key management personnel were £89,40912023.. £79,596). The charity trustee5 were not paid or received any other benefits from employment with the charity in the year12023.' £nill. No charity trustee received payment for professional or other services Supplied to the charity IZ023.- £nil). Trustee5' expenses include the payment or reimbursement of travel and subsistence costs totalling £28012023.. £197) relating to attendance at meetings of the trustees. Staff numbers The average monthly number of employees during the year was.. 2024 No. 2023 No. Management and administration Fundraising Campaign5, science and Education 14 Related party transactions There are no related party tian5actlQn5 to di5clo5e foi 2024 (ZO2 3". none). There are no donations from related pariies which are outside the normal course of business and no restricted donations from related parties. 49

Breast Cancer UK Limited Notes to the financial 5taternent5 For the year ended 31 March 2024 l O Taxation The charitable company Is exempi from corporatlon tax as all Its income Is charitable and is applied for charitable purposes. I l Debtors 2024 2023 Monies owed Other debtors Prepayments and accrued income 17,204 9,546 164,332 12,183 24.889 1 ,674 191,082 38.746 12 Creditors= amounts falling due within one year 2024 2023 Trade credltors Taxation and social security Grants payable Other creditors Accruals 20,401 12,975 139,514 3,345 9,136 15,414 83,769 9.927 185.371 109,110 13 Credltors: amounts falllng due after one year 2024 2023 Granis payable Inoie 141 126,424 108,428 126,424 108,428 14 Grants payable Grants payable included in the financial statements as follows.. 2024 2023 Grants payable is included within.. Current liabilities Non-current1Sablliiies 139,514 126,424 83,769 108,428 265,938 192.197 Movements in the year-. Balance at the beginning of the year Released from previous periods Amount accrued in the year 192,197 (125,532) 199,273 252.281 160.084) 265,938 192.197 15 Pension scheme The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund. The charge to profir or1055 in respect of defined contribution scheme5 was £20,010 12023 £13,424). 50

Breast Cancer UK Limited Notes to the financial 5taternent5 For the year ended 31 March 2024 16 Analysis of net assets between funds General unrestricted Total funds Designated Restricred Net current assets Long term liabilities 1 ,495,563 {126.4241 712.782 48,925 2.257,270 (126,424) Net assets at the end of the year 1,369.139 712.782 48.925 2.130,846 17 Movements in funds Incoming At the start resources & of the year gains Outgoing resource5 & losses At the end Transfers of the year Restrlcted funds: Young people educational resource Breast cancer in men resource Bisphenols research project Chemicals movement General science research 47,570 1,567 19,802 2,450 80,000 47,570 1,355 11,3301 (19,8021 12,4501 (i 00,0001 20,000 Total restrlcted funds 151,389 (123,5821 48,925 Unrestricted funds= Designated funds.. Science Grani Budget Conversion of Online Quiz HRT Scieniific brief Breast Feeding resource BCUK Prevenrion Conference 2025 Outreach Programme Science Foundation Award Seed Aw¢ird5 Reduce your Risk impact study Developmeni of supper clubs Developmeni of Devolved parliaments outreach Economic analysis tool BCUK branding review Mobilisation campaign BCUK Podcast BCUK Corporate film Accessibility Audit Website update5 420,000 io,000 9,000 5,000 (200,000) 147,6201 11 0,0001 19,000) 15,0001 172,380 36.000 37,000 200,000 50.000 50.000 23.400 24,317 5,000 5,000 20,000 15.000 20.36S i 0.000 6,500 i 0.000 36,000 37,000 200.000 97,620 50,000 23,400 24,317 5,000 47.620 15,0001 {11,8001 8,200 15,000 17.365 io,000 6,500 io,000 13,0001 Total designated funds 444,000 512.582 (243,8001 712,782 General funds 1,157,844 7,003.924 (792,6291 1.369,139 Total unrestricted funds 1.601,844 1,516.506 11.036.429) 2.081,921 Total funds 1.7S3,233 1,537.624 11.160.011) 2.130.846 51

Breast Cancer UK Limited Notes to the financial 5taternent5 For the year ended 31 March 2024 17. Movements in funds (Continued) Purposes of restricted funds Income, which is received for Specific purpose5, as for example grant5 and donations atcounted for as restricted funds, with expenditure usually attributed over a specific period of time. The charity manages restricted funds carefully. keep expenditure under regular review. and aim to meet the specified purposes. Purp05e5 Of designated fund5 Designated funds are the funds which have been set aside out of unrestricted funds by the trustees for specific PLsfposes. Movements In funds Iprlor yearl Balance ar Incoming April resources & Ourgoing resources & losses Balance ai 31 March 2023 2022 gains Transfers RestrSc(ed funds: Breast Density Research Project Oxysterols Project Creation and development of DLT Young people educational resource 8rea5t cancer in men resource Bisphenols research project Chemicals movement General Science research 2,994 12,9941 86 17,570 17,570 19,752 1861 30.000 2,391 50 25,000 80.000 47.570 1.567 19,802 2.450 80.000 (18,4801 86 (22,5501 Total restricted funds 57,972 137,441 141,0301 12,9941 151,389 Unrestrlcted funds.. Designated funds.. Science Grant Budget CRM Developn7ent Conversion of Online Quiz HRT Scientific brief 8reast Feeding resource 200000 220000 420000 (25,0001 i 0000 9,000 5.000 i 0000 9.000 5,000 Total designated funds 225,000 244.000 125,0001 444,000 General funds 596,1 $2 1 ,204,398 (645,7001 2,994 1, I S7,844 Total unrestricted funds 821,152 1,448,398 1670,700) 2,994 1 ,601,844 Total funds 879.124 1,585.839 1711,730) 1.753.233 52

Breast Cancer UK Limited Notes to the financial 5taternent5 For the year ended 31 March 2024 18 Reconciliation of net Income l (expendlture) to net cash flow from operarlng activitles 2024 2023 Net income I lexpenditurel for the reporting period (as per the statement of financial attivities) Dividends, interest and rent from investments Ilncreaselldecrease in debtors Increaselldecreasel in creditors 377,613 874,109 172,647) (1 $2.3361 94,257 114,471} 113,364) 164,3001 Net cash provlded by I (used In) operatlng actlvities 246,887 781,974 19 Analy515 Of cash and cash equivalents At31 March 2024 At l April 2023 Other changes Cash flows Cash in hand 1.932.025 319.534 2.251,559 Total cash and cash equlvalents 1,932,025 319,534 2,251,559 20 Legal status nf thp charlty The chariry is a company limited by guarantee and has no share capiial. The liabiliry of each member in the event of winding up is limited to £ l. 53

breast cancer uk. [e-mail] @£ www.breastcanceruk.org.uk '@BreastCancer UK o @breastcanceruk ,,facebook.com/breastcanceruk linkedin.com/company/breast-cancer-uk '￿[ Breast Cancer UK {2019} BM Box 7767 London WCIN 3XX Tel: [phone] Preventlon saves Ilves In